
Treatment of Midgut Neuroendocrine Tumors
This video examines current options for the treatment of midgut neuroendocrine tumors and highlights results of the NETTER-1 trial.
In this video, Jonathan Strosberg, MD, of the Moffitt Cancer Center, discusses current options for the treatment of midgut neuroendocrine tumors; highlights results of the NETTER-1 trial, which showed improved progression-free survival with lutetium-177 (177Lu)–Dotatate in this patient population; and discusses the use of radionuclide therapy in other types of neuroendocrine tumors.
Results of the phase III NETTER-1 trial were recently
Dr. Strosberg spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held last month in San Francisco.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.